Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.
A team of faculty and student researchers at Texas A&M University-Corpus Christi (TAMU-CC), in partnership with the National Oceanic and Atmospheric Administration and Precision Toxicological ...